Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljae458 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Atsuyuki Igarashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Pruritus, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maruho Co. Ltd., Chugai Pharmaceutical Co. Ltd..
Abstract (Originalsprache)
Background
A phase III clinical trial in Japanese children aged 6–12 years with atopic dermatitis (AD) and inadequately controlled moderate-to-severe pruritus found that 16 weeks of nemolizumab treatment [30 mg every 4 weeks (Q4W)] was clinically effective and tolerable, with early improvement in pruritus and associated skin signs and a positive impact on patient quality of life (QoL).
Objectives
To report the findings from the long-term extension period of the study, and evaluate the efficacy and safety profiles of nemolizumab when administered concomitantly with topical agents over 68 weeks.
Methods
The study included a 16-week randomized placebo-controlled double-blind parallel-group period during which patients received nemolizumab 30 mg or placebo Q4W; those who completed this period could enter a 52-week long-term treatment period during which all patients received nemolizumab Q4W. Efficacy endpoints assessed treatment impact on pruritus, AD signs and QoL. Treatment-emergent adverse events (TEAEs) were tabulated to evaluate long-term safety. The study was registered with the Japan Registry of Clinical Trials (jRCT2080225289).
Results
Among the 89 paediatric patients evaluated, efficacy outcome measures showed a tendency toward improvement between weeks 16 and 68, and sustained efficacy during the subsequent follow-up period after treatment cessation. At week 68, among patients who received nemolizumab treatment throughout the study, the mean (SD) change from baseline in the 5-level itch score was −1.8 (0.8), the mean (SD) percentage change from baseline in the Average Pruritus Numerical Rating Scale score was −65.9 (25.0), and the mean (SD) percentage change from baseline in the Eczema Area and Severity Index score was −77.1 (23.1). Data from the Dermatitis Family Impact questionnaire indicated that the burden of housework on family members and parent/caregiver fatigue were reduced and the sleep quality of family members was improved by week 16, with further improvement at week 68. The overall safety profile was similar to that recorded in nemolizumab-treated patients aged ≥ 13 years, with no late-onset TEAEs seen over long-term treatment.
Conclusions
These data confirm the safety of long-term nemolizumab for paediatric patients with AD, and demonstrate improvements in pruritus, skin symptoms, and patient and caregiver QoL over 68 weeks of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan.
- Igarashi Dermatology Higashi Gotanda, Tokyo, Japan.
- Department of Pediatrics, Daisan Hospital, The Jikei University School of Medicine, Tokyo, Japan.
- Clinical Development Department, Maruho Co., Ltd., Kyoto, Japan.
ORCID-Profile: Atsuyuki Igarashi, Toshio Katsunuma, Hiroshi Komazaki
Förderung
- Maruho Co. Ltd.
- Chugai Pharmaceutical Co. Ltd.
Zitieren
APA
Igarashi, A., Katsunuma, T., Nagano, Y., & Komazaki, H. (2025). Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae458
Vancouver
Igarashi A, Katsunuma T, Nagano Y, Komazaki H. Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljae458
BibTeX
@article{Igarashi2025,
author = {Igarashi, Atsuyuki and Katsunuma, Toshio and Nagano, Yuko and Komazaki, Hiroshi},
title = {Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljae458}
}
EUVIMED